

C1 32. (Twice amended) A method for the administration of a taxane to a human subject in need thereof, said method comprising systemically administering a complete dose of said taxane to said subject in a volume of less than 250 ml.

C2 72. (Amended) An article of manufacture according to claim 71, wherein said formulation is stable for at least 3 days.

C3 75. (Amended) An article of manufacture according to claim 74, wherein said liquid formulation of taxane is free of surfactants.

C4 79. (Amended) The formulation of claim 46 wherein said nanoparticles have a mean particle size in the range of about 29 nm up to about 400 nm.

80. (Amended) The formulation of claim 46 wherein said dry powder formulation of taxane is suitable for the treatment of tumors in the brain or peritoneal cavity.

C5 86. (Amended) The formulation of claim 52 wherein said drug nanoparticles are contained within protein microparticles having a size of about 1-10 μ m.

C6 89. (Amended) The article of claim 88 wherein said drug formulation is a dry powder.

90. (Amended) The article of claim 88 wherein the drug formulation is a liquid.

91. (Amended) The article of claim 88 wherein said drug is hydrophobic.

Please add new claims 94-121 as follows:

94. (New) A formulation according to claim 49 wherein said formulation further comprises one or more of albumin, a polyalkylene glycol, or an oil.

95. (New) A formulation according to claim 94 wherein said oil is an oil-soluble vitamin.

96. (New) A formulation according to claim 95 wherein said vitamin is vitamin A, vitamin D, vitamin E or vitamin K.

c1 97. (New) A formulation according to claim 49 wherein said taxane is non-crystalline.

98. (New) A formulation according to claim 52 wherein said protein is albumin.

99. (New) A formulation according to claim 52 wherein said formulation is solid or liquid.

100. (New) A method according to claim 61 wherein said active agent is selected from the group consisting of an anti-neoplastic, an anesthetic and a hormone.

101. (New) An article of manufacture according to claim 73 wherein said protein is albumin.

102. (New) An article of manufacture according to claim 73 wherein said formulation is solid or liquid.

103. (New) An article of manufacture according to claim 73 wherein said drug is selected from the group consisting of an anti-neoplastic, an anesthetic and a hormone.

104. (New) An article of manufacture according to claim 103 wherein said anti-neoplastic is a taxane.

105. (New) An article of manufacture according to claim 103 wherein said anesthetic is propofol.

106. (New) An article of manufacture according to claim 103 wherein said hormone is a thyroid hormone.

107. (New) A formulation according to claim 73 wherein said drug is non-crystalline.

108. (New) A formulation according to claim 73 wherein said nanoparticles are suitable for administration to a subject by oral, topical, ocular, intramuscular, intravenous, intraperitoneal, intraarterial, intraurethral, intrathecal, or inhalation administration

109. (New) An article of manufacture according to claim 88 wherein said formulation is solid or liquid.

110. (New) An article of manufacture according to claim 88 wherein said drug is selected from the group consisting of an anti-neoplastic, an anesthetic and a hormone.

111. (New) An article of manufacture according to claim 110 wherein said anti-neoplastic is a taxane.

112. (New) An article of manufacture according to claim 110 wherein said anesthetic is propofol.

113. (New) An article of manufacture according to claim 110 wherein said hormone is a thyroid hormone.

114. (New) An article of manufacture according to claim 88 wherein said drug is non-crystalline.

115. (New) A formulation according to claim 92 further comprising one or more of albumin, a polyalkylene glycol, and an oil.

116. (New) A formulation according to claim 115 wherein said oil is an oil-soluble vitamin.

C7 117. (New) A formulation according to claim 115 wherein said vitamin is vitamin A, vitamin D, vitamin E or vitamin K.

118. (New) A formulation according to claim 92 wherein said paclitaxel is non-crystalline.

119. (New) A formulation according to claim 93 further comprising one or more of albumin, a polyalkylene glycol, and an oil.

120. (New) A formulation according to claim 119 wherein said oil is an oil-soluble vitamin.

121. (New) A formulation according to claim 119 wherein said vitamin is vitamin A, vitamin D, vitamin E or vitamin K.
